Press Release on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts less than Nifty Microcap 250 and 5.7 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nephrocare Health Services Limited (NephroPlus), Asia's largest dialysis network, reported strong FY26 results with revenue of Rs. 998.8 crore, up 32.2% YoY, driven by 16.6% growth in treatment volumes and a 13.3% increase in revenue per treatment. International revenue contribution rose from 31.8% to 41.8%, reflecting a favorable mix shift toward higher-priced markets. Adjusted EBITDA grew 37.6% to Rs. 238.1 crore with margin expansion of 100 bps to 23.8%. Adjusted PAT surged 74.6% to Rs. 128.3 crore. Return on Capital Employed improved to 22.8% from 19.9% YoY. The company operates 520+ dialysis centres across India, Nepal, Philippines, Uzbekistan, and Saudi Arabia.
Strong operational and financial performance with robust revenue growth, margin expansion, and improving returns signals solid execution. The shift toward international markets and scalable operating model positions the company well for sustained growth.